Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
Department of Urology, University Hospital, LMU Munich, Munich, Germany.
Eur J Radiol. 2021 Mar;136:109540. doi: 10.1016/j.ejrad.2021.109540. Epub 2021 Jan 12.
To evaluate the efficacy and safety of urgent percutaneous embolization for the treatment of acute renal hemorrhage.
All patients undergoing endovascular embolization at our hospital for bleeding from renal artery branches between January 2010 and June 2020 were retrospectively evaluated. Periprocedural characteristics, technical details, clinical outcomes, and complications were documented.
Seventy-six patients with a mean age of 67.3 ± 12.9 underwent 86 procedures. The most common cause of hemorrhage was iatrogenic (63/76), including 44 patients presenting after partial nephrectomy. Bleeding was successfully controlled in 80 of 86 procedures (92.8 % technical success), and clinical success (defined as control of bleeding with endovascular embolization) was achieved in 72 of 76 patients (94.5 %) with embolization, including seven patients undergoing re-intervention. In univariate analysis, risk factors for clinical failure were antiplatelet agents (p = 0.033), and technical failure (p < 0.001); and technical failure was the only significant risk factor in multivariate analysis. Only one patient (1.3 %) needed nephrectomy. AKI was seen after 16 (21 %) procedures, and preprocedural increased creatinine (≧1.8) and decreased GFR (<60) were risk factors for AKI (p = 0.022 and p = 0.020). In all patients except one, renal functions returned to baseline. One patient died because of pulmonary embolism (in-hospital mortality 1.3 %).
Interventional embolization is feasible, safe, and effective in the treatment of renal hemorrhages. Among others, the complication management with minimally invasive procedures allows urologists to safely perform partial nephrectomy even in patients with central, large, and endophytic tumors, thereby preserving kidney function in these patients.
评估紧急经皮栓塞治疗急性肾出血的疗效和安全性。
回顾性分析 2010 年 1 月至 2020 年 6 月期间在我院行血管内栓塞治疗的肾动脉分支出血患者。记录围手术期特征、技术细节、临床结果和并发症。
76 例患者的平均年龄为 67.3±12.9 岁,共进行了 86 次手术。出血的最常见原因为医源性(63/76),包括 44 例在部分肾切除术后出现。86 次手术中 80 次(92.8%)成功止血,76 例患者中 72 例(94.5%)通过栓塞治疗实现临床成功(定义为通过血管内栓塞控制出血),包括 7 例再次介入治疗的患者。单因素分析显示,临床失败的危险因素为抗血小板药物(p=0.033)和技术失败(p<0.001);多因素分析显示,技术失败是唯一显著的危险因素。仅 1 例(1.3%)患者需要行肾切除术。16 次(21%)手术出现急性肾损伤(AKI),术前血肌酐升高(≧1.8)和肾小球滤过率降低(<60)是 AKI 的危险因素(p=0.022 和 p=0.020)。除 1 例患者外,所有患者的肾功能均恢复至基线水平。1 例患者因肺栓塞死亡(住院死亡率 1.3%)。
介入栓塞治疗肾出血是可行、安全且有效的。除其他外,通过微创处理并发症使得泌尿外科医生能够安全地进行部分肾切除术,即使在中央、大的和内生性肿瘤患者中也是如此,从而在这些患者中保留了肾功能。